Eugene Bauer - 05 Nov 2025 Form 3 Insider Report for Evommune, Inc.

Reporting relationship: Chief Medical Officer, Director
Issuer ticker: EVMN on NYSE
Reported as of: 05 Nov 2025
Net transaction value: $0
SEC form: 3
Accepted by SEC: 05 Nov 2025, 19:59:19 UTC
Prior SEC filing: 09 Nov 2021
Next SEC filing: 12 Nov 2025
Source filing: View source filing
Reporting owner signature: /s/ Gregory S. Moss, Attorney-in-Fact

Key filing fact

Eugene Bauer filed Form 3 for Evommune, Inc. on 05 Nov 2025.

Key facts

This page summarizes Eugene Bauer's Form 3 filing for Evommune, Inc..
0 reported transactions and 7 derivative rows are listed below.
Accepted by SEC: 05 Nov 2025, 19:59.

Change

Previous filing in this sequence was filed on 09 Nov 2021.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Official SEC source

Ownership activity is grounded in SEC Form 3 disclosures.

View source filing

Reporting Owners (1)

CIK 0001678620 Primary reporting owner

Bauer Eugene

Relationship: Chief Medical Officer, Director
Address: C/O EVOMMUNE, INC., 1841 PAGE MILL ROAD, SUITE 100, PALO ALTO
Signature: /s/ Gregory S. Moss, Attorney-in-Fact
Signature date: 05 Nov 2025

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

EVMN holding

Common Stock

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after: 246,484
Date: 05 Nov 2025
Ownership: Direct
Footnotes: F1

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

EVMN holding Derivative

Series Seed Preferred Stock

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after
Date: 05 Nov 2025
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 24,225
Exercise price
Footnotes: F2

EVMN holding Derivative

Series B Preferred Stock

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after
Date: 05 Nov 2025
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 1,587
Exercise price
Footnotes: F3

EVMN holding Derivative

Employee Stock Option (Right to Buy)

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after
Date: 05 Nov 2025
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 118,449
Exercise price: $3.07
Footnotes: F4

EVMN holding Derivative

Employee Stock Option (Right to Buy)

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after
Date: 05 Nov 2025
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 30,807
Exercise price: $3.58
Footnotes: F5

EVMN holding Derivative

Employee Stock Option (Right to Buy)

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after
Date: 05 Nov 2025
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 57,634
Exercise price: $3.84
Footnotes: F6

EVMN holding Derivative

Employee Stock Option (Right to Buy)

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after
Date: 05 Nov 2025
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 7,139
Exercise price: $1.71
Footnotes: F7

EVMN holding Derivative

Employee Stock Option (Right to Buy)

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after
Date: 05 Nov 2025
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 17,982
Exercise price: $2.99
Footnotes: F8

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 8 footnotes

Footnote F1

Includes 11,688 restricted stock units ("RSUs"). Each RSU represents the contingent right to receive one share of common stock of the Issuer. One fourth (1/4) of the RSUs shall vest on each of December 9, 2025, December 9, 2026, December 9, 2027 and December 9, 2028, subject to the Reporting Person's continuous service through each such vesting date.

Footnote F2

The Series Seed Preferred Stock is convertible into Common Stock on a 1-for-8.518 basis and has no expiration date. Upon the closing of the Issuer's initial public offering ("IPO"), all shares of Series Seed Preferred Stock will be converted into shares of Common Stock of the Issuer.

Footnote F3

The Series B Preferred Stock is convertible into Common Stock on a 1-for-7.8721 basis and has no expiration date. Upon the closing of the Issuer's IPO, all shares of Series B Preferred Stock will be converted into shares of Common Stock of the Issuer.

Footnote F4

One fourth (1/4) of the shares subject to the option award vested on May 11, 2023 and the remaining shares subject to the option vested or shall vest in thirty-six (36) equal monthly installments thereafter, subject to the Reporting Person's continuous service through such vesting date.

Footnote F5

One fourth (1/4) of the shares subject to the option award vested on January 13, 2024 and the remaining shares subject to the option vested or shall vest in thirty-six (36) equal monthly installments thereafter, subject to the Reporting Person's continuous service through such vesting date.

Footnote F6

One fourth (1/4) of the shares subject to the option award vested on May 12, 2024 and the remaining shares subject to the option vested or shall vest in thirty-six (36) equal monthly installments thereafter, subject to the Reporting Person's continuous service through such vesting date.

Footnote F7

One fourth (1/4) of the shares subject to the option award vested on January 6, 2025 and the remaining shares subject to the option vested or shall vest in thirty-six (36) equal monthly installments thereafter, subject to the Reporting Person's continuous service through such vesting date.

Footnote F8

One fourth (1/4) of the shares subject to the option award shall vest on December 9, 2025 and the remaining shares subject to the option shall vest in thirty-six (36) equal monthly installments thereafter, subject to the Reporting Person's continuous service through such vesting date.

We use cookies and similar technologies to provide certain features, enhance the user experience and, if you allow them, measure engagement and deliver advertising. Analytics and marketing storage stay off until you grant consent. By clicking on "Agree and continue", you declare your consent to the use of the selected optional cookies. to update or revoke optional consent for future visits. For more information, see our Privacy Policy .